India Pharma Outlook Team | Wednesday, 08 April 2026
Merck is moving to strengthen its global production network, placing boost filtration supply at the center of its latest Bengaluru facility.
The company has added new production lines for filtration hardware systems in 2025 and plans to begin manufacturing Pellicon® 2 Ultrafiltration Cassettes in 2026 at its Peenya site.
The Merck Bengaluru facility expansion focuses on supporting the production of life-saving medicines and vaccines by ensuring consistent access to high-quality filtration solutions.
The Peenya plant, operational since 2006, has evolved into a global hub for filtration hardware and has steadily scaled up capabilities, including prefilter cartridge manufacturing added in 2022.
Also Read: How Digital Maturity is Powering Pharma's GMP Evolution
“These products are essential to producing life-saving medicines and vaccines,” said Tony Qiu, Head of APAC Operations, Life Science Business, Merck. “By expanding manufacturing in India, we are strengthening global supply chains while also supporting local innovation and skills development.”
Pellicon 2 ultrafiltration cassettes play a key role in bioprocessing and downstream purification workflows, enabling efficient and reliable filtration in pharmaceutical and life sciences applications. With this addition, the company is enhancing its ability to meet rising global demand for advanced filtration technologies used in drug manufacturing.
The Merck Bengaluru facility expansion also highlights India’s growing role in the company’s global manufacturing network. The move aligns with the government’s Make in India initiative, which promotes advanced manufacturing, local value creation, and innovation in healthcare and life sciences.
.jpg)
